drug · small molecule
LENALIDOMIDE
Marketedupdated 3mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 66 investigational indications.
targets
CRL4(CRBN) E3 ubiquitin ligase
all catalysts(2)
Trials studying LENALIDOMIDE
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- phase3A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- phase2Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- phase2Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
- phase1A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
- phase3A Study of Daratumumab
- phase2Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 27, 2027
257 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Mar 8, 2028method-of-use (U-1983)US 87419291.6y
- Mar 8, 2028method-of-use (U-1983)US 87419291.6y
- Mar 8, 2028method-of-use (U-1983)US 87419291.6y
- Mar 8, 2028method-of-use (U-1983)US 87419291.6y
- Mar 8, 2028method-of-use (U-1983)US 87419291.6y
- Mar 8, 2028method-of-use (U-1983)US 87419291.6y
- Apr 27, 2027compositionUS 7465800257d
- Apr 27, 2027compositionUS 7465800257d
- Apr 27, 2027compositionUS 7465800257d
- Apr 27, 2027compositionUS 7465800257d
- Apr 27, 2027compositionUS 7465800257d
- Apr 27, 2027compositionUS 7465800257d
FDA exclusivities (12)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
News(7)
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 8d ago
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysStrong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…biospace · 12d ago
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.fiercebiotech · 13d ago
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.biopharma_dive · 29d ago
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.biopharma_dive · 2mo ago
- CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineA Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.biopharma_dive · 3mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that